Yousif Capital Management Increases Stake in Labcorp Holdings

Institutional investor boosts ownership in medical research company

Apr. 12, 2026 at 11:56am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate financial machinery and equipment, conveying a sense of the complex infrastructure underlying the medical research industry.Institutional investors continue to see value in Labcorp's diversified medical research and diagnostics business.Durham Today

Yousif Capital Management LLC increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 21.6% in the fourth quarter, according to a recent regulatory filing. The firm now owns 11,364 shares of the medical research company's stock, valued at $3,083,000 as of its most recent SEC disclosure.

Why it matters

Labcorp is a major player in the medical research and diagnostics industry, and changes in institutional ownership can signal broader market trends or investor sentiment around the company's performance and future prospects.

The details

Yousif Capital Management's increased stake in Labcorp comes as other institutional investors have also been active in the stock. In the third quarter, Victory Capital Management Inc. boosted its Labcorp holdings by 20%, while Wellington Management Group LLP and Marshall Wace LLP also made significant purchases. The stock has traded in a range of $209.38 to $293.72 over the past 12 months.

  • Yousif Capital Management increased its Labcorp stake in the fourth quarter of 2025.
  • The firm's latest 13F filing with the SEC was released on April 12, 2026.

The players

Yousif Capital Management LLC

An institutional investment firm that manages a portfolio of equity and fixed-income securities.

Labcorp Holdings Inc.

A global life sciences company that provides comprehensive clinical laboratory and drug development services.

Got photos? Submit your photos here. ›

The takeaway

The increased stake by Yousif Capital Management in Labcorp suggests continued institutional investor confidence in the company's long-term growth potential within the medical research and diagnostics sector.